title: "Companion diagnostics": has their time come and gone?
abstract: Rapid development of molecularly targeted drugs requires a "companion diagnostic" that could delay drug development and limit availability of active drugs for relevant patients. Were the negative results from MetMab studies in patients with advanced non-small cell lung cancer due to drug failure or failure of the right companion diagnostic?
authors: Department of Medicine and Pathology, University of Colorado Cancer Center, Aurora, Colorado. fred.hirsch@ucdenver.edu.
authors: Fred R
authors: FR
authors: Hirsch
authors: Department of Medicine and Pathology, University of Colorado Cancer Center, Aurora, Colorado.
authors: Paul A
authors: PA
authors: Bunn
authors: Department of Medicine, Smillow Cancer Center, Yale School of Medicine, New Haven, Connecticut.
authors: Roy S
authors: RS
authors: Herbst
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D000069347:Erlotinib Hydrochloride; D005260:Female; D006801:Humans; D008297:Male; D019859:Proto-Oncogene Proteins c-met / Q000096:biosynthesis*; D011799:Quinazolines / Q000008:administration & dosage*
chemical_list: D000911:Antibodies, Monoclonal; D011799:Quinazolines; D000069347:Erlotinib Hydrochloride; C491743:MET protein, human; D019859:Proto-Oncogene Proteins c-met; C584058:onartuzumab